SH5-07 (SH-5-07)

Catalog No.S7923 Batch:S792301

Print

Technical Data

Formula

C29H28F5N3O5S
Molecular Weight 625.61 CAS No. 1456632-41-9
Solubility (25°C)* In vitro DMSO 100 mg/mL (159.84 mM)
Ethanol 100 mg/mL (159.84 mM)
Water Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description SH5-07 is a robust hydroxamic acid-based STAT3 inhibitor, which induce antitumor cell effects in vitro and antitumor response in vivo against human glioma and breast cancer models.
Targets
STAT3 [1]
In vitro SH5-07 blocks STAT3 DNA binding activity in vitro and in human glioma, breast, and prostate cancer cells and in v-Src-transformed murine fibroblasts. STAT3-dependent gene transcription is blocked along with Bcl-2, Bcl-xL, Mcl-1, Cyclin D1, c-Myc and Survivin expression[1].
In vivo In mouse xenograft models of glioma and breast cancer, administration of SH5-07 effectively inhibits tumor growth[1].

Protocol (from reference)

Cell Assay:[1]
  • Cell lines

    Normal mouse fibroblasts (NIH3T3)

  • Concentrations

    0-8 μM

  • Incubation Time

    24-48 h

  • Method

    Cells are treated with 0-8 μM agent for 24-48 h. For cell cycle profile analysis, cells are harvested and fixed with 70% ice-cold ethanol and stained with propidium iodide (PI). For apoptosis analysis, cells are collected and stained with FITC-Annexin V using Apoptosis Detection Kit. Both the DNA content of cells and the Annexin V-positive cells are analyzed by FACScan flow cytometer. Cell cycle phase distribution is analyzed using the Cell-Fit program. Data acquisition is gated to exclude cell doublets.
Animal Study:[1]
  • Animal Models

    female athymic nude mice

  • Dosages

    3, 5 or 6 mg/kg

  • Administration

    oral gavage/tail vein injection

Selleck's SH5-07 (SH-5-07) has been cited by 2 publications

Activation of STAT3 through combined SRC and EGFR signaling drives resistance to a mitotic kinesin inhibitor in glioblastoma [ Cell Rep, 2022, 39(12):110991] PubMed: 35732128
Activation of STAT3 through combined SRC and EGFR signaling drives resistance to a mitotic kinesin inhibitor in glioblastoma [ Cell Rep, 2022, 39(12):110991] PubMed: 35732128

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.